Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-97637 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-97637, RRID:AB_11190113
- Product name
- Rat Monoclonal BCMA/TNFRSF17 Antibody
- Antibody type
- Monoclonal
- Description
- Protein G purified.
- Reactivity
- Human
- Host
- Rat
- Isotype
- IgG
- Vial size
- 0.05 mg
- Concentration
- 1.0 mg/ml
- Storage
- Store at -20C. Avoid freeze-thaw cycles.
Submitted references The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects.
TACI regulates IgA production by APRIL in collaboration with HSPG.
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
Neoplasia (New York, N.Y.) 2010 May;12(5):366-75
Autoantibody-producing RP105(-) B cells, from patients with systemic lupus erythematosus, showed more preferential expression of BCMA compared with BAFF-R than normal subjects.
Koarada S, Tada Y, Sohma Y, Haruta Y, Suematsu R, Mitamura M, Inoue H, Ehara H, Tokoro Y, Ohta A, Nagasawa K
Rheumatology (Oxford, England) 2010 Apr;49(4):662-70
Rheumatology (Oxford, England) 2010 Apr;49(4):662-70
TACI regulates IgA production by APRIL in collaboration with HSPG.
Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T
Blood 2007 Apr 1;109(7):2961-7
Blood 2007 Apr 1;109(7):2961-7
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Immunostaining of HEK 293 cells transfected with a human BCMA expression plasmid (left panel), or mock transfected (right panel). Method: 3 days after transfection of cells with the indicated constructs, cells were fixed with acetone or 4% formaldehyde for 5 min. at room temperature. Slides were blocked with normal IgG, and incubated for 1 hour with 5ug/ml MAb to BCMA (human) (Vicky-1) in 1% BSA in 1x PBS. After washes in PBS, samples were incubated with the secondary antibody for 1 hour, washed in PBS and revealed with StreptABComplex/HRP (Vector) and AEC.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Detection of endogenous human BCMA with MAb to BCMA (human) (Vicky-1). Method: U266 cells (2x10^5) were incubated on ice for 30 min. with 0.2ug of MAb to BCMA (human) (Vicky-1) or an isotype control in 25ul FACS buffer (PBS, 5% fetal calf serum, 0.02% azide). The primary antibody was revealed with PAb to Rat IgG (R-PE) and then analyzed by flow cytometry.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Analysis using the FITC conjugate of NBP1-97637. Staining of 10^6 Jurkat cells using BCMA (human), mAb (Vicky-1) (FITC conjugate) at a concentration of 50ug/ml.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Analysis using the PE conjugate of NBP1-97637. Staining of 10^6 U266 cells using BCMA (human), mAb (Vicky-1) (PE conjugate) at a concentration of 10ug/ml.